irsogladine has been researched along with 1-methyl-3-isobutylxanthine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kyoi, T; Noda, K; Oka, M; Ukai, Y | 2 |
2 other study(ies) available for irsogladine and 1-methyl-3-isobutylxanthine
| Article | Year |
|---|---|
Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Anti-Ulcer Agents; Brain; Cattle; Cyclic AMP; Cyclic GMP; Gastric Mucosa; Hydrolysis; Isoenzymes; Male; Myocardium; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Rats, Sprague-Dawley; Stomach; Triazines | 2004 |
Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Anti-Ulcer Agents; Bucladesine; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Gastric Mucosa; Humans; Isoenzymes; Isoquinolines; Neutrophils; Rolipram; Sulfonamides; Superoxides; Triazines | 2004 |